1GLP-3RT 20mg provides a larger-dose blend of peptides for research applications, maintaining consistent purity.
$185.00
21 in stock
An investigational triple agonist acting on GIP, GLP-1, and glucagon receptors simultaneously.
In late-stage clinical trials for obesity and type 2 diabetes; not yet an approved medication.
Early trial data show substantial weight loss, often exceeding what’s seen with single- or dual-agonist peptides, plus improved metabolic markers.
Not FDA-approved. Any version sold outside a clinical trial is an unapproved, unregulated research chemical with no verified human safety or purity data.
